Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Brain Neoplasms 4Pancreatic Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma 2Plasma EGFR Mutation-positive Lung Cancer 1Nasopharyngeal Carcinoma 1NSCLC 1Esophageal Neoplasms 1

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × icotinib × Clear all
NCT02328261 2014-12-31

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
66 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡